Freeline Therapeutics Holdings plc (FRLN)
Market Cap | 28.91M |
Revenue (ttm) | n/a |
Net Income (ttm) | -100.67M |
Shares Out | 64.97M |
EPS (ttm) | -2.12 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 8,457 |
Open | 0.460 |
Previous Close | 0.452 |
Day's Range | 0.431 - 0.460 |
52-Week Range | 0.390 - 1.280 |
Beta | 0.51 |
Analysts | Buy |
Price Target | 5.10 (+1,033.33%) |
Earnings Date | Apr 4, 2023 |
About FRLN
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201,... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for FRLN stock is "Buy." The 12-month stock price forecast is $5.1, which is an increase of 1,033.33% from the latest price.
News

Freeline Therapeutics to Host Full Year 2022 Financial Results Call
LONDON, March 28, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, April 4, 2...

Freeline Announces Closing of Sale of Its CMC-Focused German Subsidiary
LONDON, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the closing of the previously announced sale of its CMC-focused German subsidiary, Freeline ...

Freeline Reports January 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LONDON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on January 31, 2023, the Company granted two newly hired employees non-statutory option...

Freeline Publishes Preclinical Proof-of-Concept Data for FLT190, its AAV Gene Therapy Candidate for Fabry Disease, in the Nature Journal Gene Therapy
Data show increased enzyme activity and reduction of harmful substrate, an established biomarker of efficacy in Fabry disease, in key tissues and organs

Freeline Reports December 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LONDON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on December 30, 2022, the Company granted four newly hired employees non-statutory opti...

Freeline Receives Approval to Transfer to Nasdaq Capital Market
LONDON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that it received approval from the Nasdaq Stock Market LLC (“N...

Freeline Reports Third Quarter 2022 Financial Results and Corporate Update
Entered into definitive agreement to sell CMC-focused German subsidiary and related IP for $25 million, while retaining rights to AAVS3 capsid and maintaining access to capabilities and technologies

Freeline to Present at the Stifel Healthcare Conference
LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that Chief Executive Officer Michael Parini will participate in a fireside chat at the Stife...

Freeline Reports October 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on October 31, 2022, the Company granted three newly hired employees non-statutory opti...

Freeline Announces September 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LONDON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on September 30, 2022, the Company granted five newly hired employees non-statutory opt...

Freeline Initiates Dosing of Second Cohort in MARVEL-1 Trial of FLT190 Gene Therapy Candidate for People with Fabry Disease
LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the first patient has been dosed in the second dose cohort of the Phase 1/2 MARVEL-1 cl...

Freeline Announces August 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Freeline Announces Inducement Grants Freeline Announces Inducement Grants

Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) Could Find Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN), indicating that the stock has found support. This, combined with an ...

5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.

Freeline Reports Second Quarter 2022 Financial Results and Business Highlights
Six patients dosed in B-LIEVE trial of FLT180a in hemophilia B in four months and initial and emerging cohort one data reported, followed by NEJM publication of B-AMAZE long-term data

Freeline Announces July 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on July 29, 2022, the Company granted its newly hired Chief People Officer Nicole Jones...

Here's Why Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) Could be Great Choice for a Bottom Fisher
Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical cha...

New England Journal of Medicine Publishes Positive Long-Term Data on Freeline's Gene Therapy Candidate FLT180a for People with Hemophilia B
Treatment with FLT180a led to durable expression of coagulation factor IX (FIX) and strong decreases in both bleeding rates and need for FIX replacement among patients Treatment with FLT180a led to du...

Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) Upgraded to Buy: Here's What You Should Know
Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock highe...

Freeline Posts Cases Of Lower FIX Expression, Higher Liver Enzymes From Hemophilia Candidate
Freeline Therapeutics Holdings plc (NASDAQ: FRLN) announced the presentation of safety and initial efficacy data from the first cohort of the Phase 1/2 B-LIEVE trial for FLT180a for hemophilia B. As o...

Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress
FLT180a generated protective FIX levels with no bleeding or need for FIX replacement

Genespire appoints Dr. Sabah Sallah as Chief Medical Officer
Genespire appoint s Dr. Sabah Sallah as Chief Medical Officer

Freeline Announces June 2022 Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on June 30, 2022, the Company granted a newly hired employee non-statutory options to p...

Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress
LONDON, June 24, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the upcoming presentation of new and important clinical data for its AAVS3-based gene therap...

Freeline Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B
Initial cohort one data suggest predictable and sustained Factor IX normalization, supporting additional dosing at the same low dose with the same optimized, prophylactic immune management regimen